Danaher Upgrades Patient Monitoring Through Masimo Acquisition

Danaher just made a decisive move into patient monitoring by agreeing to buy Masimo in an all cash deal. The company said it has a definitive agreement to acquire Masimo for $180 per share in cash, valuing the deal at an enterprise value of about $9.9 billion, including assumed debt and net of acquired cash. Danaher also put some math on the table that investors can actually model, calling it roughly 18x estimated 2027 EBITDA, or about 15x if you include the full benefit of expected annual synergies.

Masimo is a leader in pulse oximetry and other patient monitoring solutions, and Danaher is positioning that as a natural add on to its Diagnostics segment. If the deal closes, Danaher said Masimo will operate as a standalone company within Diagnostics, alongside businesses like Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics. The pitch is growth with guardrails - a new asset in the portfolio without turning the whole segment into a science fair.

Danaher expects Masimo to be accretive to adjusted diluted net earnings per share by $0.15 to $0.20 in the first full year after completion, and about $0.70 by the fifth full year. Danaher said Masimo is expected to deliver high single digit core revenue growth over the long term, generate more than $530 million of EBITDA in 2027, and support more than $125 million of annual cost synergies plus more than $50 million of annual revenue synergies by the fifth full year. This is not a bet on a single year, it is a plan to stack small wins until they look big, with revenue synergies that are meant to show up steadily, not magically.

As for timing and closing risk, the companies are keeping it conventional. Danaher said the transaction is expected to close in the second half of 2026, subject to customary conditions including regulatory clearances and Masimo shareholder approval, and Danaher expects to fund it with cash on hand and debt financing. Until then, investors get the familiar waiting game where the price is fixed, the headlines are variable, and the spread becomes its own little sport.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726